<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95858">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020356</url>
  </required_header>
  <id_info>
    <org_study_id>12 385 02</org_study_id>
    <secondary_id>AOL 2012</secondary_id>
    <nct_id>NCT02020356</nct_id>
  </id_info>
  <brief_title>Music Therapy in Alzheimer's Disease</brief_title>
  <acronym>PRE-MUSICAL</acronym>
  <official_title>Impact of Music Therapy on Prescription of Neuroleptics in Alzheimer's Disease ou Related Symptoms Associated With Disruptive Behaviours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the protocol is to demonstrate that the use of music therapy may make
      it possible to discontinue at least one of neuroleptic treatment in patients with AD or
      related symptoms complicated by behavioral disorders such as agitation and aggressiveness
      evaluated using the Neuropsychiatric Inventory (NPI).

      The study hypothesis is that music therapy may have a positive impact on patients with AD
      complicated by behavioral disorders by reducing the intensity of oppositional behaviour and
      aggressiveness and allowing a diminution of neuroleptic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A technique of receptive music therapy to induce relaxation has been developed in the
      university hospital of Montpellier: the &quot;U&quot; sequence. The musical sequence lasts 20 minutes
      and is made up of several phases that progressively induce a relaxed state in the patient.
      This effect is obtained by modulating the rhythm of the music, the orchestral formation,
      frequencies and volume. The phase of maximum relaxation is followed by a stimulating phase.
      These musical sequences have been specially designed by the music publishers Music Care©.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Neuroloeptic reduction dose</measure>
    <time_frame>during 2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Benefit obtained in terms of the reduction in neuroleptic dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of treatment effect</measure>
    <time_frame>1, 2 and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score on the Cohen-Mansfield scale, Overall NPI score, Quality of life in Alzheimer's disease scale (QOL-AD)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Music therapy session's effects</measure>
    <time_frame>4 weeks after completion of music therapy sessions</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportions of patients in the two groups who discontinued neuroleptics, Scores on the Cohen-Mansfield scale, Dose of neuroleptics</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer's Type Dementia With Disruptive Behaviour</condition>
  <arm_group>
    <arm_group_label>Music therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;U&quot; sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Music therapy</intervention_name>
    <description>&quot;U&quot; sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase.</description>
    <arm_group_label>Music therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either sex aged 65 years and over, living in an institution for the
             dependent elderly for at least 3 months

          -  Subjects with Alzheimer-type dementia (DSM-IV and  National Institute of Neurological
             and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders
             Association (NINCDS-ADRDA) criteria)or related symptoms

          -  If treated, Treated for at least 6 months with a stable dose of cholinesterase
             inhibitor or memantine

          -  Mini-Mental State Examination (MMSE) score between 5 and 20

          -  Patients with disruptive behaviour (at least one disruptive item on the NPI:
             oppositional behaviour/aggressiveness/agitation, aberrant motor behaviour, with a
             severity score grater than or equal to 4) and treated with at least one neuroleptic
             whose dose which could not be decreased because of persistence of the behavioural
             problems for at least 15 days.

        Exclusion Criteria:

          -  Decompensated physical disease

          -  Inability to give informed consent

          -  Lack of health insurance coverage

          -  Non-corrected hearing impairment

          -  treatment ongoing with two or more neuroleptics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe ARBUS, MD</last_name>
    <phone>0534557510</phone>
    <phone_ext>33</phone_ext>
    <email>arbus.c@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline PEYROT, CRA</last_name>
    <phone>0561778486</phone>
    <phone_ext>33</phone_ext>
    <email>peyrot.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves ROLLAND, PhD</last_name>
      <phone>0534557607</phone>
      <phone_ext>33</phone_ext>
      <email>rolland.y@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Yves ROLLAND, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EHPAD La Villegiale</name>
      <address>
        <city>Castres</city>
        <state>Tarn</state>
        <zip>81100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FEUGAS , MD</last_name>
      <phone>0618379153</phone>
      <phone_ext>33</phone_ext>
      <email>r-feugas@chic-cm.fr</email>
    </contact>
    <investigator>
      <last_name>FEUGAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Residence Christian Bressole</name>
      <address>
        <city>Castres</city>
        <state>Tarn</state>
        <zip>81100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HALWANI , MD</last_name>
      <phone>0563722040</phone>
      <phone_ext>33</phone_ext>
      <email>agirbressolle@orange.fr</email>
    </contact>
    <investigator>
      <last_name>HALWANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EHPAD L'Oustal d'en Thibaud</name>
      <address>
        <city>Labruguiere</city>
        <state>Tarn</state>
        <zip>81290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice RASCOL, MD</last_name>
      <phone>0563502251</phone>
      <phone_ext>33</phone_ext>
      <email>patrice.rascol@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice RASCOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EHPAD Les Quietudes</name>
      <address>
        <city>Lautrec</city>
        <state>Tarn</state>
        <zip>81440</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth DELGA, MD</last_name>
      <phone>0607026966</phone>
      <phone_ext>33</phone_ext>
      <email>elisabeth.delga@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth DELGA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005 Jun;20(6):523-30.</citation>
    <PMID>15920712</PMID>
  </reference>
  <reference>
    <citation>Aldridge D. Music and Alzheimer's disease--assessment and therapy: discussion paper. J R Soc Med. 1993 Feb;86(2):93-5.</citation>
    <PMID>8433315</PMID>
  </reference>
  <reference>
    <citation>Benoit M, Robert PH, Staccini P, Brocker P, Guerin O, Lechowski L, Vellas B; REAL.FR Group. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J Nutr Health Aging. 2005;9(2):95-9.</citation>
    <PMID>15791352</PMID>
  </reference>
  <reference>
    <citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989 May;44(3):M77-84.</citation>
    <PMID>2715584</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Disruptive behaviours</keyword>
  <keyword>Neuroleptics</keyword>
  <keyword>Music therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
